{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:25:05Z","timestamp":1790799905023,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Wilhelm-Sander Foundation, Munich, Germany","award":["2011.069.1"],"award-info":[{"award-number":["2011.069.1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12943-016-0497-3","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T03:12:16Z","timestamp":1455246736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?"],"prefix":"10.1186","volume":"15","author":[{"given":"Inga","family":"Bekes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W. P.","family":"Friedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"M\u00f6bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"W\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"key":"497_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/aje\/kwp314","volume":"171","author":"MA Gates","year":"2010","unstructured":"Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171:45\u201353.","journal-title":"Am J Epidemiol"},{"key":"497_CR2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/his.12349","volume":"64","author":"M K\u00f6bel","year":"2014","unstructured":"K\u00f6bel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunhistochemistry. Histopathology. 2014;64:1004\u201313.","journal-title":"Histopathology"},{"key":"497_CR3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ctrv.2014.12.003","volume":"41","author":"C Della Pepa","year":"2015","unstructured":"Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, et al. Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev. 2015;41:136\u201343.","journal-title":"Cancer Treat Rev"},{"key":"497_CR4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1525-1438.2005.00441.x","volume":"15","author":"RC Bast","year":"2005","unstructured":"Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA-125 and beyond. Int J Gynecol Cancer. 2005;15:274\u201381.","journal-title":"Int J Gynecol Cancer"},{"key":"497_CR5","first-page":"4043","volume":"31","author":"CG Gerestein","year":"2011","unstructured":"Gerestein CG, Eijkemans MJ, Bakker J, Elgersma OE, van der Burg ME, Kooi GS, et al. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer. Anticancer Res. 2011;31:4043\u20139.","journal-title":"Anticancer Res"},{"key":"497_CR6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ygyno.2007.02.027","volume":"105","author":"MM Gilani","year":"2007","unstructured":"Gilani MM, Karimi Zarchi M, Ghaemmaghami F, Behtash N, Mousavi AS, Ansaripoor S. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol Oncol. 2007;105:780\u20133.","journal-title":"Gynecol Oncol"},{"key":"497_CR7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/00016340701226138","volume":"86","author":"A Ayhan","year":"2007","unstructured":"Ayhan A, Guven S, Guven ES, Kucukali T. Is there a correlation between tumor marker panel and tumor size and histopathology in well-staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand. 2007;86:484\u201390.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"497_CR8","first-page":"367103","volume":"2014","author":"T Feigenberg","year":"2014","unstructured":"Feigenberg T, Clarke B, Virtanen C, Plotkin A, Letarte M, Rosen B, et al. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int. 2014;2014:367103.","journal-title":"Biomed Res Int"},{"key":"497_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2012.05.002","volume":"127","author":"D Herr","year":"2012","unstructured":"Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, et al. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol. 2012;127:210\u20136.","journal-title":"Gynecol Oncol"},{"key":"497_CR10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ncb1752","volume":"10","author":"A Taddei","year":"2008","unstructured":"Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol. 2008;10:923\u201334.","journal-title":"Nat Cell Biol"},{"key":"497_CR11","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.fertnstert.2013.01.120","volume":"99","author":"D Herr","year":"2013","unstructured":"Herr D, Fraser HM, Konrad R, Holzheu I, Kreienberg R, Wulff C. Human chorionic gonadotropin controls luteal vascular permeability via vascular endothelial growth factor by down-regulation of a cascade of adhesion proteins. Fertil Steril. 2013;99:1749\u201358.","journal-title":"Fertil Steril"},{"key":"497_CR12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gtc.2005.12.006","volume":"35","author":"SM Rosenberg","year":"2006","unstructured":"Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin North Am. 2006;35:189\u201399.","journal-title":"Gastroenterol Clin North Am"},{"key":"497_CR13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0002-9378(70)90031-1","volume":"106","author":"K Hirabayashi","year":"1970","unstructured":"Hirabayashi K, Graham J. Genesis of ascites ovarian cancer. Am J Obst Gynecol. 1970;106:492\u20137.","journal-title":"Am J Obst Gynecol"},{"key":"497_CR14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10456-005-9001-1","volume":"8","author":"S Ramakrishnan","year":"2005","unstructured":"Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005;8:169\u201382.","journal-title":"Angiogenesis"},{"key":"497_CR15","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-05-1181","volume":"12","author":"MH Pourgholami","year":"2006","unstructured":"Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res. 2006;12:1928\u201335.","journal-title":"Clin Cancer Res"},{"key":"497_CR16","first-page":"276","volume":"54","author":"TA Olson","year":"1994","unstructured":"Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994;54:276\u201380.","journal-title":"Cancer Res"},{"key":"497_CR17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.1997.537","volume":"76","author":"S Yamamoto","year":"1997","unstructured":"Yamamoto S, Konishi I, Mandai M, Kuroda H, Kometsu T, Nanbu K, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 1997;76:1221\u20137.","journal-title":"Br J Cancer"},{"key":"497_CR18","first-page":"823","volume":"5","author":"D Hazelton","year":"1999","unstructured":"Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res. 1999;5:823\u20139.","journal-title":"Clin Cancer Res"},{"key":"497_CR19","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-10-0974","volume":"16","author":"SK Chambers","year":"2010","unstructured":"Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010;16:5320\u20138.","journal-title":"Clin Cancer Res"},{"key":"497_CR20","first-page":"156","volume":"31","author":"GK Siddiqui","year":"2010","unstructured":"Siddiqui GK, Elmasry K, Wong Te Fong AC, Perrett C, Morris R, Crow JC, et al. Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Eur J Gynaecol Oncol. 2010;31:156\u20139.","journal-title":"Eur J Gynaecol Oncol"},{"key":"497_CR21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1447-0756.2008.00967.x","volume":"35","author":"Y Kobayashi","year":"2009","unstructured":"Kobayashi Y, Terauchi F, Nishi H, Fujitou A, Itou H, Isaka K. A case of advanced ovarian cancer upstaged on the bases of pleural washing cytology. J Obstet Gynaecol Res. 2009;35:588\u201392.","journal-title":"J Obstet Gynaecol Res"},{"key":"497_CR22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1152\/ajplegacy.1946.147.2.237","volume":"147","author":"RG Abell","year":"1946","unstructured":"Abell RG. The permeability of blood capillary sprouts and newly formed blood capillaries as compared to that of older blood capillaries. Am J Physiol. 1946;147:237\u201341.","journal-title":"Am J Physiol"},{"key":"497_CR23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1272\/jnms.74.223","volume":"74","author":"R Futami","year":"2007","unstructured":"Futami R, Miyashita M, Nomura T, Makino H, Matsutani T, Sasajima K, et al. Increased serum vascular endothelial growth factor following major surgical injury. J Nippon Med Sch. 2007;74:223\u20139.","journal-title":"J Nippon Med Sch"},{"key":"497_CR24","first-page":"1527","volume":"20","author":"C Justinger","year":"2008","unstructured":"Justinger C, Schl\u00fcter C, Oliviera-Frick V, Kopp B, Rubie C, Schilling MK. Increased growth factor expression after hepatic and pancreatic resection. Oncol Rep. 2008;20:1527\u201331.","journal-title":"Oncol Rep"},{"key":"497_CR25","first-page":"73","volume":"29","author":"VL Vinokurov","year":"1983","unstructured":"Vinokurov VL, Kolosov AE, Iurkova LE. Clinico-morphological characteristics of marginal epithelial ovarian tumors. Vopr Onkol. 1983;29:73\u20138.","journal-title":"Vopr Onkol"},{"key":"497_CR26","doi-asserted-by":"crossref","unstructured":"Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annual Review of Cell and Developmental Biology. 2010","DOI":"10.1146\/annurev-cellbio-092910-154002"},{"key":"497_CR27","first-page":"5721","volume":"9","author":"AT Byrne","year":"2003","unstructured":"Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causesdramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9:5721\u20138.","journal-title":"Clin Cancer Res"},{"key":"497_CR28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1349-7006.1996.tb02127.x","volume":"87","author":"J Mu","year":"1996","unstructured":"Mu J, Abe Y, Tsusui T, Yamamoto N, Tai XG, Niwa O, et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res. 1996;87:963\u201371.","journal-title":"Jpn J Cancer Res"},{"key":"497_CR29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3835(97)00350-9","volume":"121","author":"EM Hartenbach","year":"1997","unstructured":"Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor (VEGF) expression and survival in human endothelial ovarian carcinomas. Cancer Lett. 1997;121:169\u201375.","journal-title":"Cancer Lett"},{"key":"497_CR30","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"497_CR31","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/humrep\/den479","volume":"24","author":"M Rodewald","year":"2009","unstructured":"Rodewald M, Herr D, Duncan WC, Fraser HM, Hack G, Konrad R, et al. Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum Reprod. 2009;24:1191\u20139.","journal-title":"Hum Reprod"},{"key":"497_CR32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ijc.2910520115","volume":"52","author":"V M\u00f6bus","year":"1992","unstructured":"M\u00f6bus V, Gerharz CD, Press U, Moll R, Beck T, Mellin W, et al. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer. 1992;52:76\u201384.","journal-title":"Int J Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-016-0497-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T23:57:55Z","timestamp":1654300675000},"score":1,"resource":{"primary":{"URL":"http:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-016-0497-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1186\/s12943-016-0497-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]},"article-number":"13"}}